MSKCC PCNSL: Two-factor prognostic model for Primary CNS Lymphoma. Simple and validated independently of therapy type.
MSKCC Risk Class
Median Overall Survival
Favorable clinical profile. Intensive therapy often achieves long-term durability in this class.
Verified
Last Review: 2026-07-17
| Score | Risk Group | Median Survival (mo) |
|---|---|---|
| 0 | Class 1 (Low) | 44 |
| 1 | Class 2 (Intermediate) | 32 |
| 2 | Class 3 (High) | 8.5 |
Abrey LE et al. • Journal of Clinical Oncology. 2006;24(36):5711-5.
View SourceLast Comprehensive Review: 2026-07-17
Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
